Skip to main content
NIKI logo

NIKI · Niki BioSolutions, Inc.

Track NIKI — free
$7.00 +0.49 (+7.53%)
Market Cap
$5.30M
Shares
814,375

Price & Indicators

20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$6.51 Open$6.48 Day$6.48–6.70 Since split$6.51–10.17 Avg vol 30d39K Short int4K · 0.5% float · 1.0d Short vol44% DataJul 2026–Sep 2026

Raw chart and full-history price indicators begin at the captured split on Jul 20, 2026; bars on opposite sides are not compared.

The closing range begins at the captured split on Jul 20, 2026.

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
Trailing 12 months
Net income (TTM)
Trailing 12 months
Revenue growth YoY
Year over year
Operating margin
Trailing 12 months
P / E (TTM)
Trailing earnings
FCF yield
TTM · current market cap
Return on invested capital
Trailing 12 months
Net cash
Latest balance sheet
Dividend yield
Trailing 12 months
Shares change YoY
Year over year · more shares
Price change (1Y)
Trailing year
Short interest
0.5%
Latest settlement · 1.0 days to cover
View all 114 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Limited Sentiment Neutral Fundamentals Weak Quant / Vol Very High
Market backdrop VIX 14.3 · calm Equity put/call 0.47
Technical
price trend
Sell
50 / 200-day cross No cross
RSI (14) 32
neutral
52-week position 0%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Limited
Not enough data for a confident read.
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50/200-day averages unavailable
Institutional flow Distributing
-38% holders QoQ · +2 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.53% of float · ▼ -82.6% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
5 holders — mid 3-yr range
Squeeze score 25
low risk · 0–100
Fundamentals
Weak
Revenue growth −67%
Y/Y
EPS growth +76%
Y/Y
Free cash flow $-1.8M
Quant / Vol
risk profile
Very High
Volatility 82%
annualized · 1-yr
Max drawdown −36%
past year
ATR 12.6%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
1 · 3 · 0
50 / 200-day cross
No cross Neutral
RSI (14)
32 Neutral
52-week position
0% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50/200-day averages unavailable
Institutional flow Distributing
-38% holders QoQ · +2 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.53% of float · ▼ -82.6% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
5 holders — mid 3-yr range
Price context
position in its range since split · 2026-07-20
Range low $7 Now $7 · 0% Range high $10

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
NIKI
Niki BioSolutions, Inc.
this stock
$5.30M -66.7% 0.5%
VRTX
Vertex Pharmaceuticals Inc / Ma
$140.51B +23.1% +46.2% 32.3 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
$86.84B +9.3% +20.8% 20.9 2.3%
ARGX
Argenx SE
$65.63B +25.3% 1.9%
CSLLY
Csl Ltd
$59.96B 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
5
% held
1.2%
Net QoQ
-6.2K sh
Top holder
JANE STREET GROUP, LLC
Held Float
View
Short & Settlement
Short Interest Falling
Shares short
4.3K
Days to cover
1.0d
Change
-20.5K sh
View
Short Volume
Short vol %
44%
As of
Sep 3, 2026
Short Total
View
Fails to Deliver
FTD shares
619
Value
$5.4K
As of
Aug 14, 2026
View
Off-Exchange
Off-exchange %
49.0%
Week of
Jul 27, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$431.4K
Net income (FY)
$-1.4M
EPS diluted
$-1.90
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 21, 2026
This year
14
View

Performance

Raw-price comparisons begin at the captured split on Jul 20, 2026; windows that need an earlier baseline remain unavailable.

5D 20D 120D MTD YTD
NIKI -13.7% -29.9% -5.1%
SPY +0.3% +0.6% +16.7% +0.8% +13.4%
vs SPY -13.9% -30.5% -5.9%
Key facts CIK 1734005 CUSIP 653942102 13F (30d) 3 filings 3 filers Visit website Investor relations